#United States #Dividend #Shareholders #Exton #West Pharmaceutical

West Pharmaceutical Services Increases Quarterly Dividend

EXTON, Pa., October 19, 2026 – In a promising announcement for investors, the Board of Directors of West Pharmaceutical Services, Inc. (NYSE: WST), a prominent force in the injectable drug administration sector, declared a quarterly dividend of $0.26 per share. This figure represents an impressive 18% increase from the previous dividend of $0.22 per share paid in the last quarter. Moreover, this marks the thirty-fourth consecutive year of dividend growth for the Company, demonstrating its commitment to shareholder returns.

The newly declared dividend is scheduled for payment on November 18, 2026, with shareholders of record by November 11, 2026, benefiting from this increase. “This decision to boost the dividend reflects our continuous growth and robust financial performance, and it emphasizes our dedication to returning value to our investors,” commented the Board during the announcement.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc. is not just a leader but a pioneering partner for both established and emerging drug developers. The Company delivers innovative and high-quality solutions that enhance the safety and efficacy of injectable drug delivery. With a workforce exceeding 10,000 employees across 50 locations, including 26 manufacturing facilities worldwide, West produces over 41 billion components and devices annually to support the global healthcare industry.

Founded in Exton, Pennsylvania, West achieved remarkable net sales of $3.07 billion in its fiscal year 2025, showcasing its potent growth trajectory within the industry. The Company is publicly traded on the New York Stock Exchange under the ticker symbol WST and is also a constituent of the respected Standard & Poor's 500 index. For those looking for more insights, the Company's official website is a resourceful platform: www.westpharma.com.

West Pharmaceutical Services emphasizes excellence and innovation in its operations, ensuring patients receive life-enhancing medications through advanced containment and delivery solutions. The Company’s broad array of cutting-edge technologies contributes significantly to improving patient outcomes in healthcare settings.

In addition to its core business objectives, West’s consistent commitment to enhancing shareholder value is reflected in its recurrent dividend increases and solid market performance. As the pharmaceutical and biotech sectors continue to evolve, West stands ready to navigate challenges and sustain growth, all while ensuring that its stakeholders benefit from the Company's success. The announcement of the latest dividend underscores West's resilience and strategic focus within a competitive industry landscape.

For more information, feel free to contact:
* Michele Polinsky
Vice President, Global Communications
Phone: +1-610-594-3054
Email: [email protected]

West Pharmaceutical Services remains a steadfast partner in the healthcare industry, consistently working toward delivering innovative solutions and enhancing the quality of life worldwide.